These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3224082)

  • 1. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
    Nicholson S; Halcrow P; Sainsbury JR; Angus B; Chambers P; Farndon JR; Harris AL
    Br J Cancer; 1988 Dec; 58(6):810-4. PubMed ID: 3224082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
    Nicholson S; Sainsbury JR; Halcrow P; Chambers P; Farndon JR; Harris AL
    Lancet; 1989 Jan; 1(8631):182-5. PubMed ID: 2463445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
    Wright C; Nicholson S; Angus B; Sainsbury JR; Farndon J; Cairns J; Harris AL; Horne CH
    Br J Cancer; 1992 Jan; 65(1):118-21. PubMed ID: 1346366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
    Harris AL; Nicholson S; Sainsbury JR; Farndon J; Wright C
    J Steroid Biochem; 1989; 34(1-6):123-31. PubMed ID: 2576295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.
    Nicholson S; Richard J; Sainsbury C; Halcrow P; Kelly P; Angus B; Wright C; Henry J; Farndon JR; Harris AL
    Br J Cancer; 1991 Jan; 63(1):146-50. PubMed ID: 1846551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
    Sainsbury JR; Farndon JR; Needham GK; Malcolm AJ; Harris AL
    Lancet; 1987 Jun; 1(8547):1398-402. PubMed ID: 2884496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
    Anderson ED; Forrest AP; Levack PA; Chetty U; Hawkins RA
    Br J Cancer; 1989 Aug; 60(2):223-6. PubMed ID: 2527549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
    Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
    Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure.
    Nicholson S; Wright C; Sainsbury JR; Halcrow P; Kelly P; Angus B; Farndon JR; Harris AL
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):811-4. PubMed ID: 2285594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. St. Gallen endocrine response classes predict recurrence rates over time.
    Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
    Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
    Okunade G; Green AR; Ying M; Agrawal A; Paish EC; Aleskandrany M; Winterbottom L; Hassell K; Morgan DA; Ellis IO; Cheung KL
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):76-82. PubMed ID: 19515574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor and other oncogenes as prognostic markers.
    Harris AL; Nicholson S; Sainsbury R; Wright C; Farndon J
    J Natl Cancer Inst Monogr; 1992; (11):181-7. PubMed ID: 1627426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.
    Knoop AS; Bentzen SM; Nielsen MM; Rasmussen BB; Rose C
    J Clin Oncol; 2001 Jul; 19(14):3376-84. PubMed ID: 11454885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
    Holdaway IM
    Aust N Z J Surg; 1981 Aug; 51(4):345-7. PubMed ID: 6944051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
    Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
    Boylan M; van den Berg HW; Lynch M
    Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.